Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 1/20 | 0.58 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.32 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.32 |
| ▸ | FABP3 | P05413 | 2/20 | 0.31 |
| ▸ | FABP4 | P15090 | 2/20 | 0.31 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.31 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16694196 | 0.77 | HDAC4 (0.40) | ROCK2PTPN5 | |
| SCHEMBL29590068 | 0.77 | HDAC4 (0.40) | ROCK2PTPN5 | |
| SCHEMBL29670251 | 0.75 | HDAC4 (0.39) | ROCK2PTPN5 | |
| SCHEMBL16947505 | 0.73 | ROCK2 (1.00) | ROCK2 | |
| SCHEMBL31547997 | 0.73 | ROCK2 (0.45) | ROCK2GABRA1GABRB2FABP3FABP4 | |
| SCHEMBL2727228 | 0.73 | ROCK2 (0.49) | ROCK2GABRA1GABRB2FABP3FABP4 | |
| SCHEMBL30869371 | 0.72 | ROCK2 (0.50) | ROCK2GABRA1GABRB2FABP3FABP4 | |
| SCHEMBL4003562 | 0.72 | ROCK2 (0.37) | ROCK2PTPN5 | |
| SCHEMBL29424818 | 0.71 | ROCK2 (0.48) | ROCK2GABRA1GABRB2FABP3FABP4 | |
| SCHEMBL29527590 | 0.71 | MAOA (0.40) | PTPN5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107406424-B | Estrogen receptor modulators and uses thereof | 豪夫迈·罗氏有限公司 | 2020-08-25 | — | — | CN | disclosed |
| EP-3233828-B1 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | HOFFMANN LA ROCHE (CH) | 2020-03-04 | — | — | EP | disclosed |
| US-9845291-B2 | Estrogen receptor modulators and uses thereof | GENENTECH, INC. (US) | 2017-12-19 | — | — | US | disclosed |
| CN-107406424-A | Estrogen receptor modulators and uses thereof | 豪夫迈·罗氏有限公司 | 2017-11-28 | — | — | CN | disclosed |
| US-20170197915-A9 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | GENENTECH, INC. (US) | 2017-07-13 | — | — | US | disclosed |
| US-20160304450-A1 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | GENENTECH, INC. (US) | 2016-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170197915-A9 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | ESR2, ESR1, GPER1 | ROCK2 3696/4885GABRA1 237/4885GABRB2 321/4885 |
| US-20160304450-A1 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | ESR2, ESR1, GPER1 | ROCK2 3696/4885GABRA1 237/4885GABRB2 321/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.